The 8;21 translocation is a common chromosomal abnormality in acute myeloid leukemia (AML). We recently identified a naturally occurring leukemogenic splice variant, AML1-ETO9a (acute myeloid leukemia-1 transcription factor and the eighttwenty-one corepressor-9a), of t(8;21). To understand the leukemic potential of AML1-ETO9a, we performed microarray analysis with the murine multipotential hematopoietic FDCPmix A4 cell line. We identified changes in expression of various genes including CD44. CD44 is a type I transmembrane protein and functions as the major cellular adhesion molecule for hyaluronic acid, a component of the extracellular matrix. CD44 is expressed in most human cell types and is implicated in myeloid leukemia pathogenesis. We show that the presence of AML1-ETO9a significantly increased the expression of CD44 at both RNA and protein levels. Furthermore, the CD44 promoter is bound by AML1-ETO9a and AML1-ETO at the chromatin level. In addition, in the AML1-ETO9a leukemia mouse model CD44 is regulated in a cell context-dependent manner. Thus, our observations suggest that AML1-ETO and its splice variant AML1-ETO9a are able to regulate the expression of the CD44 gene, linking the 8;21 translocation to the regulation of a cell adhesion molecule that is involved in the growth and maintenance of the AML blast/stem cells.
Introduction
The AML1-ETO (acute myeloid leukemia-1 transcription factor and the eight-twenty-one corepressor) fusion protein plays a key role in the pathogenesis of acute myeloid leukemia (AML); 1, 2 however, various mouse models have shown its requirement for a secondary mutagenic event for full transformation. [3] [4] [5] [6] [7] More recently, our laboratory identified a single nucleotide insertion, which truncated the AML1-ETO protein from 83 kDa to a 62 kDa protein named 'AML1-ETOtr' that rapidly promoted leukemia following retroviral infection and bone marrow transplant. 8 Moreover, we subsequently showed that most patients with t(8;21) analyzed harbored the splice variant, AML1-ETO9a, which is quite similar to the truncated AML1-ETO. 9 This isoform, containing the exon 9a splice form of ETO, provides a stop codon right after the last amino acid encoded by exon 8/9a junction of ETO ( Figure 1a ). Using retroviral-mediated AML1-ETO9a expression and hematopoietic cell transplantation a rapid onset of leukemia in mice was observed similar to truncated AML1-ETO. 9 To investigate the role of this AML1-ETO9a form of AML1-ETO in transformation, we used the FDCP-mix A4 cell line. 10 We previously reported that expression of either AML1-ETO or AML1-ETOtr partially blocked differentiation of FDCP-mix A4 cells. 8 Here we report that these cells expressing AML1-ETO9a mimic properties of AML. On the basis of this observation, we hypothesized that the gene expression profile should be different between the control cells and AML1-ETO9a-expressing FDCPmix A4 cells and applied microarray technology to identify this differential gene expression pattern. The lists of gene expression changes in our data set show that both hematopoietic progenitor marker genes and genes involved in myeloid maturation were enhanced. We also identified genes involved in regulating proliferation. Of interest was the gene CD44, a type I transmembrane protein that functions as the major cellular adhesion molecule for hyaluronic acid and is implicated in multiple cellular processes of normal and malignant cells. 11, 12 In addition, a role for CD44 in the growth, maintenance and homing of leukemic blast/stem cells has been reported. [13] [14] [15] Northern blot, flow cytometry and promoter assays confirmed that AML1-ETO9a regulates the expression of the CD44 gene. In addition, the expression of CD44 protein on two t(8;21) cell lines displays a relatively higher signal density compared to other AML-derived cell lines, as well as higher CD44 RNA levels. Valproic acid induced re-localization of AML1-ETO and differentiation of t(8;21) Kasumi-1 cells 16 lead to a decrease in CD44 expression. Furthermore, in primary murine AML1-ETO9a leukemia samples, CD44 expression is differentially modulated in the stem and progenitor cell populations of the leukemia. Chromatin immunoprecipitation (ChIP) confirmed the binding of the human CD44 promoter by AML1-ETO9a and AML1-ETO in human cells. In addition, AML1-ETO9a bound the murine CD44 promoter region in primary AML1-ETO9a mouse leukemia cells. We observed further the upregulation of genes within a CD44 network, which are one of its ligands osteopontin (SPP1/OPN1) 17 and the Runx2 transcription factor 18 that positively regulates osteopontin expression, suggestive of a molecular loop of regulation promoted by AML1-ETO9a. Thus, these observations suggest a direct link between the 8;21 translocation and the CD44 cell adhesion molecule that is involved in the growth, maintenance and homing of the AML blast/stem cells into the stem cell niche.
Materials and methods

Cell culture
FDCP-mix A4 cells were received from Dr C Heyworth (Paterson Institute for Cancer Research, Manchester, UK) and maintained in Iscove's Modified Dulbecco's Medium (IMDM) (Invitrogen, Carlsbad, CA, USA) with 20% horse serum (SigmaAldrich, St Louis, MO, USA), 2 mM L-glutamine and 1% penicilline/streptomicine (Pen/Strep) (Invitrogen) containing 10% conditioned media of interleukin (IL)-3. K562, HL-60, U937, NB4, Kasumi-1 and SKNO-1 cells were cultured in RPMI-1640 (Invitrogen), 10% fetal bovine serum (FBS) (Omega Scientific, Tarzana, CA, USA), 2 mM glutamine and 1% Pen/ Strep. HeLa cells were maintained in Dulbecco's modification of Eagle's medium (Invitrogen), 10% FBS, 2 mM glutamine and 1% Pen/Strep. The FDCP-mix A4 cells were cultured under growth limiting conditions by substituting the 20% horse serum with FBS (Hyclone, Logan, UT, USA) and the addition of 30 ng/ ml recombinant granulocyte-colony stimulating factor (G-CSF) and 0.1 ng/ml recombinant IL-3 (Peprotech, Rocky Hill, NJ, USA). Conditioned mouse IL-3 media was produced from the X63 AG-653 myeloma cell line 19 received from Dr F Melchers (Basel Institute of Immunology, Basel, Switzerland) into IMDM with 20% horse serum, 2 mM L-glutamine, and 1% Pen/Strep. Kasumi-1 cells were treated with 1 mM valproic acid (SigmaAldrich) for 66 h or with 3 mM valproic acid for 8 h.
Establishing FDCP-mix A4 and K562 cell lines stably expressing AML1-ETO-9a, and western blot analysis A blunt-ended XbaI/EcoRI AML1-ETO9a cDNA fragment was subcloned into the HpaI site of MSCV-IRES-puromycin (MIP) or MSCV-IRES-EGFP (MIG) vector, designated as MIP-HA-AE9a or MIG-HA-AE9a, as shown in Figure 1b . Retrovirus production and infection method, and western blot analysis were performed as described previously. 8 
RNA preparation and microarray data analysis
Total RNA was extracted from cells with RNA-bee (TEL-TEXT Inc., Friendswood, TX, USA) and further purified by RNase-free DNase (Qiagen, Valencia, CA, USA). For microarray, analysis a total of 5 mg of total RNA was reverse transcribed into cDNA with an oligo(dT)-T7 polymerase primer. Subsequently, T7 polymerase was used for in vitro transcription. During transcription, cRNA was labeled with biotinylated UTP (uridine triphosphate). The resulting labeled cRNAs were fragmented and hybridized to oligonucleotide microarrays, containing probes for approximately 39 000 transcripts (GeneChip Mouse Genome 430 2.0 Array; Affymetrix, Santa Clara, CA, USA). Array was scanned after being stained with streptavidin-phycoerythrin (PE), signal amplification with biotinylated anti-streptavidin antibodies, and subsequent staining with streptavidin-PE. Raw data were normalized and scaled to an average of 5000. For a gene to be considered induced or repressed, the ratio of expression in the control and AML1-ETO9a expressed samples should be higher than 2.0. Experiments were duplicated by using independently prepared RNA samples from two independent infections. 
Northern blot
The cDNA used for probes of Sparc and Mac25 (Igfbp7) were purchased from Open Biosystems (Huntsville, AL, USA). Mac25 and Sparc clones are EMM1002-6900103 and MMM1013-63485, respectively. The cDNA inserts were both excised with NotI/SalI digestion for probes. The probe for mouse CD44 was generated by reverse transcriptase-PCR using total RNA from FDCP-mix A4 cells. The primers are (1) 5 0 -TTACCCACCATG GACCAAAT-3 0 and (2) 5 0 -GGTCACTCCACTGTCCTGGT-3 0 , which generated a 587 bp fragment of standard CD44. Northern blot analysis was further performed as described previously. 20 
Real-time PCR
Generation of AML1-ETO9a AML in mice
These experiments were performed as described previously. 9 Leukemic cells were isolated from the spleen, blood and bone marrow before the mice became moribund.
Flow cytometric analysis
Flow cytometry for the mouse leukemic samples and cell lines was performed and analyzed as described previously. 8 FITCconjugated mouse-anti-human CD44 antibody was from Sigma (F-3647). PE-conjugated mouse CD44 antibody and its isotype control were kindly provided by Charlie Surh (The Scripps Research Institute, La Jolla, CA, USA) and purchased from BDPharmigen (Franklin Lakes, NJ, USA).
Luciferase reporter assay and ChIP
PCR was used to amplify the fragment from the first ATG start codon to 2 kb upstream of the CD44 gene with primers 5 0 -TATCTCGAGGCCTGCCTCAAATATCA-3 0 , containing a XhoI site, and 5 0 -GAGAAGCTTCATGGTGTCCGGAGCGAAC-3 0 with a HindIII site. pGLX2 is from pGL2-Basic (Promega, Madison, WI, USA) in which all the known AML1 binding sites has been mutated. HA-AML1-ETO9a, HA-AML1-ETO and HAAML1b cDNA were cloned into pcDNA6.0 plasmid. The luciferase reporter transfection assay in K562 cells were performed as described previously. 20 Alternatively, MIGR1, MIGR1-HA-AML1-ETO9a or MIGR1-HA-AML1-ETO9a-R174Q (Yan et al. manuscript in preparation) were co-transfected with the pGLX2-CD44 reporter construct. For the transfection of HeLa cells, 1 Â 10 5 cells were plated per well of a 12-well plate. Cells were transfected by PolyFect (Qiagen) transfection reagent with 0.8 mg luciferase reporter plasmid in the presence of 0.2 mg pcDNA6-HA-AML1-ETO, pcDNA6-HA-AML1-ETO9a and pcDNA6-HA-AML1b. Forty-eight hours after transfection, cells were collected and assayed for luciferase activity. ChIP was performed with equal amount of K562 cells stably expressing HA-AML1-ETO9a or control cells with anti-HA antibody (Covance, Princeton, NJ, USA) as previously described. 20 ChIP was performed with equal amount of Kasumi-1 cells untreated or treated with valproic acid with rabbit-anti-AML1 9 and rabbitIgG (Sigma-Aldrich) as described previously. 21 The precipitated DNA pellet of each sample was amplified by PCR with the primers 5 0 -ACAGATATGTGGGTGGAT-3 0 /5 0 -TATGTCCTTCTG GGGCTCTC-3 0 performing 40 cycles of 95-55-721C for 1 min at each temperature. ChIP was performed with primary AML1-ETO9a-induced leukemia samples as previously described 21 with rabbit-anti-AML1
9 and rabbit-anti-HA (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Amplification of the mouse CD44 promoter region with an AML1 site was performed with the oligo's 5 0 -ACACATATTCTTCTAATCGCTGCT-'3/5'-GCCTG CCACATACACACAAT-3 0 following 40 cycles of 95-60-721C for 30 s at each temperature.
Results
Establishing the AML1-ETO9a stably expressed FDCP-mix A4 cell line and its effect on growth
To analyze the ability of the newly identified AML1-ETO9a, splice variant of AML1-ETO, to affect growth, we transduced the mouse pluripotent hematopoietic cell line FDCP-mix A4 with a retrovirus expressing AML1-ETO9a (Figure 1b 
Identification of genes altered by AML1-ETO9a in microarray
Our observation that AML1-ETO9a affects FDCP-mix A4 cells prompted us to test gene expression profiling by microarray technology to identify altered gene expression by AML1-ETO9a in this murine progenitor cell line. This approach also adds the prospect of identifying new potential AML1 and AML1-ETO/ AML1-ETO9a target genes. In total, we observed 270 transcripts upregulated and 183 downregulated by more than twofold. Among them, 75 genes are upregulated and 24 are downregulated by more than 3.5-fold. Of interest, in this upregulated list (Supplementary Table S1 ) are secreted gene products such as Cxcl7, Cxcl4 and Thrombospondin 1. Cxcl7 and Cxcl4 block megakaryocyte development, 22 while Cxcl4 also supports the survival and chemosensitivity of hematopoietic cells. 23 Thrombospondin 1 promotes granulocytic 24 and blocks megakaryocyte differentiation. 25 In addition, the cell-cycle inhibitor p16ink4A and the p53 pathway-induced Wig1 gene were both decreased in accordance with the increased cell cycle.
Other interesting gene changes between 2 and 3.5-fold include (Supplementary Table S2 ) the c-met proto-oncogene (c-met, 3.1-fold) that is the receptor for hepatocyte growth factor, 26 which is also induced eightfold, suggesting that this known oncogenic signaling pathway is putatively upregulated. In addition, as no increased apoptosis was observed associated with decreased Bcl2 (À2.6-fold), it could be suggested that the HGF/c-met signaling pathway may be blocking such a cellular response. 27 Specific genes identified as AML1 and/or AML1-ETO targets in this list include protein kinase-b (Prkcb, 2.9-fold), 28 B-cell leukemia/lymphoma 2 (Bcl2, À2.6-fold) 29 and myeloperoxidase (Mpo, 2.4-fold). 30 Various of the genes affected are involved in myeloid differentiation, such as Mpo, lysozyme (Lyzs, 2.9-fold) and neutrophil elastase (8.3-fold), in accordance with Shimada et al.
31
From the plethora of genes involved in various cellular processes, we decided to look at genes that play a role in cell growth regulation and/or are identified as hematopoietic markers. We performed Northern blot hybridization, flow cytometry or real-time PCR to confirm their changes in expression. Sparc (osteonectin) and Mac25 (Igfbp7), both of which decreased more than 10-fold are involved in the negative regulation of cell-cycle progression. 32 Figure 2a displays a good correlation between the results of microarray and Northern hybridization, and that these two genes are dramatically downregulated in the presence of AML1-ETO9a. Specifically, Sparc is known to block solid tumor growth 33 and has recently been demonstrated to be decreased in myeloid/lymphoid or mixed-lineage leukemia (MLL) rearranged and t(8;21)-associated AML. 34, 35 Furthermore, Igfbp7 was increased in the t(8;21) Kasumi-1 cell line following siRNA treatment against AML1-ETO, thus suggesting that it is also a potential direct target of AML1-ETO 36 or in our case AML1-ETO9a. Flow cytometric analysis of the mouse hematopoietic stem cell marker Sca-1, which showed a 8.5-fold increase in the microarray, displayed an increase in the expression of Sca-1 on the AML1-ETO9a FDCP-mix A4-expressing cells (Figure 2b) .
CD44 is a cell surface adhesion molecule implicated in solid tumor characteristics such as metastasis. 37 In AML, ligation of CD44 by antibodies promotes differentiation of both AML cell lines and primary samples. 38 The CD44 gene which was increased by 4.7 fold in the microarray was also induced by Northern blot, in addition to the increase of CD44 protein expression on the surface of AML1-ETO9a-infected FDCP-mix A4 cell lines (Figure 2c) . Furthermore, we also recognized a regulatory loop involving CD44. This involves upregulation of a gene that can bind as a ligand to CD44 itself, namely osteopontin (OPN1/SPP1), 17 which thus can stimulate positive feedback on CD44 expression. 39 Additionally, we observed an increased expression of the Runx family member Runx2, which positively regulates OPN1 expression. 18 Both these genes were confirmed upregulated by real-time PCR by 2.7-and 2.2-fold, respectively (Figure 2d) . Thus, these observations show a good association between microarray data and expression analysis employing various techniques.
Expression of human CD44 in myeloid leukemia cell lines full-length AML1-ETO and AML1-ETO9a protein. 9 We also performed real-time PCR to verify the level of CD44 transcript present in these 8;21-containing cell lines compared to U937 that was originally isolated from a non-t(8;21) M2 patient, in addition to K562 and HL-60. We observed an increased transcript level of CD44 in the t(8;21) cell lines compared to the other leukemia cell lines (Supplementary Figure 1B) . These observations support the idea that AML1-ETO and its AML1-ETO9a splice variant regulate the expression of CD44 on t(8;21)-positive AML cells. To elucidate the regulation of CD44 expression in AML1-ETO9a-infected FDCP-mix-A4 cells, we cloned an approximately 2 kb DNA segment upstream of the ATG start codon of the human CD44 gene containing a predicted transcriptional start site at 135 bp upstream of the ATG (À1850 bp to þ 135 bp) into the promoter-less luciferase vector pGLX2 (named pGLX2-CD44). As shown in Figure 3a , two perfect AML1 consensus binding sites and five potential weak AML1 binding sites are identified within this 2 kb DNA fragment. Transfection of this pGLX2-CD44 construct into the human myeloid cell line K562 cells yielded levels of luciferase activity more than 20-fold above the pGLX2 control, confirming that this segment contains promoter activity (data not shown). When plasmids of both pcDNA6.0-HA-AML1-ETO9a and pGLX2-CD44 construct were co-transfected into K562 cells, the CD44 promoter activity was upregulated at an average of 4.9-fold compared with the control transfection with pcDNA6.0 empty vector (Figure 3b) . Fulllength AML1-ETO also activated the CD44 promoter by an average of 3.8-fold compared with pcDNA6.0 empty vector. However, AML1b did not have much influence on the CD44 promoter with only a 1.8-fold increase compared with the empty vector. We also confirmed in HeLa cells that the regulation of the CD44 promoter is not myeloid cell specific (Figure 3b ). The overall response pattern was similar to that observed in K562 cells. To determine whether activation is dependent on AML1-ETO9a DNA binding, we co-transfected pGLX2-CD44 with AML1-ETO9a or AML1-ETO9a-R174Q. The argine (R) to glutamine (Q) mutation at position 174 of AML1 was detected in familial platelet disorder (FDP)/AML patients. 40 This mutant interacts with the AML1 heterodimer partner CBFb but is no longer able to bind DNA. 41, 42 We detected a substantial reduction of CD44 promoter activity when AML1-ETO9a-R174Q was used in the transactivation study (Figure 3c ), indicating that the interaction of AML1-ETO9a with its DNA binding sites is important for its effect on the CD44 promoter. Furthermore, AML1-ETO9a induced the CD44 mRNA and was bound to the CD44 promoter region with the two AML1 sites in a ChIP assay in the human K562 myeloid leukemia cell line stably expressing HA-AML1-ETO9a compared to the MIP empty vector control (Figure 3d ). We show further that the expression of HA-AML1-ETO full length in FDCP-mix A4 cells also increased CD44 expression (Figure 3e ), in addition to Sca1 (data not shown) as observed with AML1-ETO9a. These observations suggest that the observed upregulation in our microarray data is not specific to the FDCP-mix A4 cells, as well to the positive regulation of CD44 by AML1-ETO in these cells. We also confirmed by ChIP analysis that AML1-ETO is present in a cross-linked complex with the CD44 promoter region containing AML1 sites in Kasumi-1 cells. In addition, AML1-ETO was absent following the downregulation of CD44 expression by the recently described valproic acid re-localization of AML1-ETO and differentiation 16 of Kasumi-1 cells (Figure 3f) . Thus, these results show that AML1-ETO9a and AML1-ETO are involved in the regulation of the CD44 promoter.
Differential regulation of CD44 in AML1-ETO9a leukemic progenitor cells compared to leukemic stem cells
As CD44 expression may also be as a result of the induction of differentiation markers in FDCP-mix A4 cells by AML1-ETO9a, we investigated whether the CD44 expression level is increased during differentiation of the parental cells. We observed an increased CD44 expression in the CD11b/Gr1 double-positive population that arises throughout days 1, 3, 7 and 9 (data not shown). We therefore investigated in vivo CD44 modulation in the AML1-ETO9a leukemia mouse model. 9 These mice developed first signs of disease at 8.8 weeks (data not shown). Leukemic cells were harvested from the spleen, blood and bone marrow. Flow cytometric analysis ( Supplementary Figure 2A) for the expression of CD44 on stem cell LinÀ/cKit þ /Sca1 þ and progenitor LinÀ/cKit þ /Sca1À populations within splenocytes, blood and bone marrow leukemia cells, show that splenocytes and blood display increased expression of CD44 within the stem cell population compared to stem cells of control mice (Figure 4a ). CD44 expression was decreased in the splenocytes or relatively equivalent in the blood and in the progenitor population compared to bone marrow progenitor cells of control mice (Supplementary Figure 2B) . However, bone marrow leukemia cells displayed a lower CD44 expression in the presence of AML1-ETO9a in both the stem and progenitor populations (Figure 4b and Supplementary Figure 2B) . In addition to the downregulation of CD44 expression, we observed in valproic acid induced AML1-ETO re-localization and differentiation in Kasumi-1 cells (Figure 3f ) these experiments suggest that AML1-ETO9a and AML1-ETO are able to regulate CD44 in a cell context/tissue-dependent manner in stem/progenitor cell populations. Furthermore, they suggest that increased CD44 expression is not linked to the increase in differentiation markers observed in our microarray. We also performed ChIP assays with primary AML1-ETO9a leukemia cells and amplified the mouse CD44 promoter region containing an AML1 site bound by AML1-ETO9a (Figure 4c ). These observations encouraged the analysis of CD44 mRNA within t(8;21) AML-M2 bone marrow samples compared to non-t(8;21) AML-M2 patient bone marrow and blood samples by real-time PCR, which showed that t(8;21) patients express lower levels of CD44 compared to the nont(8;21) patients (Figure 4d ). As the t(8;21) leukemia samples are prepared from the bone marrow, this lower expression of CD44 in t(8;21) patients is consistent with the lower expression of CD44 observed in the AML1-ETO9a mouse model in the progenitor populations and bone marrow compartment. These results thus suggest a novel cell context/tissue-dependent differential regulation of CD44 expression by t(8;21) fusion products.
Discussion
We recently reported an alternatively spliced isoform of AML1-ETO, named AML1-ETO9a 9 that functions biologically similarly to our previously reported AML1-ETOtr 8 by promoting leukemia rapidly and with a similar flow cytometric leukemic phenotype in mice. 9 Interestingly, the presence of full-length AML1-ETO and AML1-ETO9a cooperate and shorten the onset of leukemia caused by AML1-ETO9a, 9 as well as changing the phenotypic aspect of the leukemia, suggestive that AML1-ETO9a or partial loss of the function of the AML1-ETO C-terminal region is a driving force of leukemic transformation in t(8;21) leukemia. We therefore investigated the transforming properties and gene expression profile of AML1-ETO9a in the murine progenitor cell line FDCP-mix A4. We observed that AML1-ETO9a has oncogenic capability by promoting cell-cycle progression under normal and growth-limiting culture conditions in this murine hematopoietic progenitor line. Furthermore, AML1-ETO9a expression affected multiple biological processes by microarray analysis, specifically deregulating more genes in the category of signal transduction and general cellular processes (total 36 genes), suggestive that the cells might be primed for a higher growth rate. At first glance, various genes involved in myeloid differentiation are upregulated, similar to an earlier microarray gene expression profile report on AML1-ETO in another murine progenitor cell line named L-G cells. 31 These genes include Mpo, lipocalin 2 (Lcn2/NGAL), lysozyme, neutrophil elastase, and the granulins A and B (also known as MRP8 and MRP14, respectively). This observation suggests that the presence of AML1-ETO or AML1-ETO9a in these two independent murine progenitor lines promotes a partial myeloid differentiation state. Furthermore, this partial differentiation is in keeping with the Mpo positive state associated with t(8;21) leukemic cells. In addition, we observed an increase in expression of genes that negatively regulate the maturation of megakaryocytes, such as Cxcl7, Cxcl4 and thrombospondin 1. Furthermore, a gene involved in promoting erythroid differentiation by enhancing TGFb/Smad4 signaling named TSC22d1v 43 is downregulated (À2.7 fold) ( Supplementary  Table S2 ) in the presence of AML1-ETO9a. Interestingly, we observed the upregulation of two stem/progenitor cell markers, Sca-1 and CD34. We specifically verified by flow cytometry that Sca-1 is upregulated at the protein level by AML1-ETO9a. Thus the gene expression changes suggest that AML1-ETO9a promotes a myeloid phenotype, inhibiting megakaryocyte and erythroid maturation, defining AML1-ETO9a transformation as a myeloid disease-expressing stem/progenitor cell markers. In this microarray analysis, it was evident that various receptor molecules and receptor ligands are affected. This prompted us to verify some of these by Northern blotting and/or protein expression analysis. We show that two secreted proteins involved in negatively regulating growth, Sparc and Igfbp7 (MAC25), are downregulated in the presence of AML1-ETO9a. Sparc was also decreased in t(8;21) patient samples. 34, 35 The other secreted protein Igfbp7 is a major factor upregulated during U937 differentiation by vitamin D3 treatment, as the cells undergo growth arrest. 44 A decrease in Igfbp7 is also associated with tumorigenesis in an in vivo mouse tumor model. 45 Thus, the decreased expression of these growth inhibitory proteins is in agreement with the increased growth observed in the AML1-ETO9a-expressing cells.
More interestingly, we identified CD44 as a target of AML1-ETO9a and confirmed that it is regulated at both RNA and protein levels. We determined that the human CD44 promoter is positively regulated by AML1-ETO9a and AML1-ETO in both myeloid and non-myeloid cells. In addition, the human CD44 promoter region containing AML1 sites is bound by AML1-ETO9a and AML1-ETO by ChIP in non-t(8;21) K562 overexpressing AML1-ETO9a and the t(8;21) Kasumi-1 cells, respectively. Furthermore, AML1-ETO9a bound the mouse CD44 promoter in primary AML1-ETO9a mouse leukemia cells and increased its expression in a cell/tissue context-dependent manner in leukemic stem cells compared to leukemic progenitors. CD44 role in homing and stem cell maintenance has been well studied. CD44-deficient mice display an impaired mobilization by G-CSF treatment, 46 and certain antibodies directed against CD44 affect stem cell maintenance after co-culture of human CD34 þ /CD38À stem cells on a stromal cell layer. 47 More recent reports have defined the CD44 receptor as an important player in hematopoietic mobilization/homing of leukemic stem cells 15, 48 and as an important target for promoting differentiation in vivo of primary leukemic samples. 14 CD44 is expressed on most leukemia cells 11 and its importance in homing of leukemic stem cells to the bone marrow suggest that it is a major player in leukemic stem cell maintenance and might be one of the earliest events of deregulated expression during leukemogenesis. In addition, we observed the deregulation of osteopontin (OPN1) a ligand of CD44 17 and the Runx2 transcription factor that positively regulates OPN1. 18 The increased expression of these factors suggest a feedback loop for continued expression of CD44, 39 signaling that is favorable for transformation 49, 50 and leukemic stem cell maintenance ( Figure 4e ). Our finding that AML1-ETO9a and AML1-ETO bind and regulate the CD44 promoter resulting in increased CD44 expression in a murine progenitor line and in primary AML1-ETO9a murine leukemia stem cells suggests (1) that AML1-ETO9a/AML1-ETO regulation of CD44 expression and function on leukemia initiating stem cells in the periphery and in the bone marrow niche may be one of the early events in t(8;21) leukemogenesis and (2) that this direct regulation of a CD44 network, which includes OPN and Runx2, promotes a continued signaling pathway that is essential in survival. 50 The decreased CD44 expression in the bone marrow niche observed in the AML1-ETO9a mouse model, which is consistent with the lower CD44 expression observed in t(8;21) bone marrow patient samples, suggests that other signaling events may be specifically modulating the regulation of CD44 by the AML1-ETO9a oncogene in this tissue (Figure 4f) . Furthermore, the observed differential CD44 regulation may influence the mobilization of AML1-ETO9a-positive stem cells to accumulate in the periphery thereby enhancing a 'metastatic'/extramedullary leukemia potential of these stem cells, which assists in the rapid disease progression in the AML1-ETO9a mouse, and could be associated with the poor prognosis related with extramedullary leukemia observed in some t(8;21) patients. 51 Alternatively, this regulatory system may be a method of targeting the leukemia initiating stem cells to the bone marrow, where CD44 is subsequently downregulated. Future investigation in patients to identify the discrepancy in CD44 expression between stem and progenitor cells should help ascertain a better way to tackle t(8;21) leukemia-initiating stem cells.
In summary, our differential gene expression profile identifies an AML1-ETO9a specific signature that displays different genes that are deregulated compared to other gene expression profile studies of AML1-ETO. However, we do find common themes; that genes involved in myeloid differentiation are upregulated, and genes that promote cell cycle are upregulated in contrast to the downregulation of genes that promote growth arrest. Thus both the full-length AML1-ETO protein and its splice isoform AML1-ETO9a may regulate specific expression profiles that promote the leukemogenic myeloid phenotype of the leukemia. Interestingly, our findings highlight a putative combinatorial therapeutic intervention strategy, whereby the direct targeting of the chimeric AML1-ETO/AML1-ETO9a protein and their target, the CD44 adhesion molecule, will 0 -untranslated region. Underlined are potential AML1 sites. Primary AML1-ETO9a murine leukemia sample was analyzed by ChIP with rabbit-anti-AML1 and anti-HA antibodies followed by the amplification by PCR of the mouse CD44 promoter for the AML1 site at position À1578. (d) Real-time PCR analysis of bone marrow prepared samples from t(8;21) AML-M2 patients (n ¼ 7) and both blood and bone marrow prepared samples from non-t(8;21) AML-M2 patients (n ¼ 10). The relative CD44 expression compared to the GAPDH level of each individual patient is represented by a dot. The bar illustrates the median expression level of each patient group. (e) AE9a-CD44 network in leukemia-initiating stem cells. AML1-ETO9a is able to directly activate CD44 gene expression, in addition to increasing the expression of both OPN1 (osteopontin) and Runx2. OPN1 itself also is positively regulated by Runx2. OPN1 binding to CD44 promotes a signaling cascade that increases active Akt promoting cell survival and proliferation. Thus the direct regulation of CD44 by AML1-ETO9a, and the induction of the CD44/ OPN1/Runx2 pathway define a mechanism of AML1-ETO9a in leukemic stem cell maintenance, migration and survival. (f) AML1-ETO9a regulates CD44 expression differentially between leukemia-initiating stem cells and leukemic progenitors. If other cellular signaling events are involved in regulating this discrepancy is unknown. This differential expression mechanism could be a procedure that promotes 'metastasis'/extramedullary leukemia by the leukemia-initiating stem cell or functions by helping this stem cell to home to the bone marrow, where CD44 is subsequently decreased on these cells. AML1-ETO9a, acute myeloid leukemia-1 transcription factor and the eight-twenty-one corepressor-9a; ChIP, chromatin immunoprecipitation; GADPH, glyceraldehyde-3-phosphate dehydrogenase.
tackle both the source of the disease and the regulatory loop involved in t(8;21) leukemic stem cell growth, maintenance and survival.
